Moutih Rafei

A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex.

Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction.

Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients.

Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine.

Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases.

Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner.

Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.

An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis.

Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis.

A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties.

[A chimeric cytokine to help autoimmune diseases].

A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo.

GIFT15 fusokine to foil immunity's follies.

A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity.

A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseases.

Development and function of innate polyclonal TCRalphabeta+ CD8+ thymocytes.

A MCP1 fusokine with CCR2-specific tumoricidal activity.

Inducible IL10(+) suppressor B cells inhibit CNS inflammation and T helper 17 polarization.

Differential effects of γc cytokines on postselection differentiation of CD8 thymocytes.

Interleukin-21 accelerates thymic recovery from glucocorticoïd-induced atrophy.

Ex vivo generation of murine IL-10-producing B cells by fusokines.

Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2.

Inducible IL10(+) Suppressor B Cells Inhibit CNS Inflammation and T Helper 17 Polarization.

A Fusion of GMCSF and IL-21 Initiates Hypersignaling Through the IL-21Rα Chain With Immune Activating and Tumoricidal Effects In Vivo.

Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation.

Restoring thymic function: Then and now.

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.

Cardiotrophin-Like Cytokine Factor 1 Exhibits a Myeloid-Biased Hematopoietic-Stimulating Function.

Mesenchymal Stem Cells Beyond Regenerative Medicine.

A Novel Sulfonyl-Based Small Molecule Exhibiting Anti-cancer Properties.

TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity.

Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal.

FcεR1-expressing nociceptors trigger allergic airway inflammation.

Thymoproteasome-Expressing Mesenchymal Stromal Cells Confer Protective Anti-Tumor Immunity Cross-Priming of Endogenous Dendritic Cells.

Autologous BMAC Therapy Improves Spinal Degenerative Joint Disease in Lower Back Pain Patients.

Cell Therapy: Types, Regulation, and Clinical Benefits.

Bone marrow aspirate concentrate versus platelet-rich plasma for treating knee osteoarthritis: a one-year non-randomized retrospective comparative study.

UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells.

Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice.

Humoral Immunity to Allogeneic Immunoproteasome-Expressing Mesenchymal Stromal Cells Requires Efferocytosis by Endogenous Phagocytes.

Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity.

LSD1 Inhibition Enhances the Immunogenicity of Mesenchymal Stromal Cells by Eliciting a dsRNA Stress Response.

Accum™ Technology: A Novel Conjugable Primer for Onco-Immunotherapy.